PROPHYLAXIS OF CERVICAL CANCER

Kirdan V.T., Trischuk N.M. National University of Pharmacy, Knarkiv, Ukraine nadezhdatr@mail.ru

Every two minutes a woman in the world dies from cervical cancer. In Ukraine, each year, about 16,000 cases of cancer of the female reproductive organs. One third of them – cervical cancer, from which kills nearly 2,000 women, mostly of reproductive age. Most cases of cervical cancer provokes human papilloma virus (HPV). Science knows more than a hundred varieties of it, although some cancer causing strains: 16-18, 45, 31 and 33. The most dangerous are the first three.

Ukraine has registered two vaccines for the prevention of precancerous lesions and cervical cancer caused by HPV, "Gardasil" and "Cervarix". These vaccines do not infect infection because they are based - virus-like particles "shell." Immune system produces antibodies to them, and when he finds similar elements in the body, begins to actively fight them. The studies of HPV vaccines have shown high efficiency in terms of protection against the types of viruses against which they were created ("Gardasil" prevents infection with HPV types 6, 11, 16 and 18, and "Cervarix" prevents infection with HPV types 16 and 18), but do not protect against infection by other HPV types

If at the time of vaccination woman has been infected with HPV types 16 or 18, the likelihood of vaccination precancerous lesions and cervical cancer caused by viruses of this type, is reduced to zero. Unfortunately, cervical cancer associated with HPV 16 and 18, only 70% of cases. The remaining 30% of cases triggers by the HPV types against which the vaccine has been developed yet. Therefore vaccination "Gardasil" or "Cervarix" cervical cancer or the risk of dysplasia is significantly reduced, but not completely disappear.

According to the U.S. Center for Disease Control, in the country of HPV vaccinated more than 7.7 million women. Marked not heavy side effects – 1:680 patients: fainting, pain and swelling at the injection site, headache, nausea, and rise in temperature.

Vaccination is carried out in the offices of vaccination in hospitals, three times in six months, at of 9 to the age 55 years. Maximum efficiency is observed if vaccinated before sexual debut. Then the girls formed immunity, so that even when in contact with an infected person, it will be protected. However, the effectiveness of the protection of the rest of the women decreased by only 2%.